Management of stage III breast cancer

Aafke H. Honkoop, John Wagstaff, Herbert M. Pinedo

Research output: Contribution to journalArticle

Abstract

Stage III breast cancer encompasses a heterogenous group of patients. According to the American Joint Committee on Cancer (AJCC) these tumors include stage IIIA and stage IIIB disease, the first generally being operable but the second inoperable. Patients with inflammatory breast cancer are also included in stage IIIB disease, and these patients have the worst prognosis. Multidisciplinary therapy has become the treatment of choice for these patients. Primary or neoadjuvant chemotherapy, followed by locoregional therapy, either surgery, radiotherapy or both, is now an accepted strategy. Most patients achieve a response to chemotherapy, resulting in downstaging of the tumor, and 5-year-survival rates have improved from 10-20% with local therapy alone to 30-60% with the multidisciplinary approach. Although many prospective, mainly phase II trials have been performed in stage III breast cancer, the optimal treatment scheme still has to be established. The role of new therapeutic strategies such as high-dose chemotherapy with hematopoietic stem cell rescue and higher dose intensity regimens with hematopoietic growth factors is currently under investigation. This article will review the literature and discuss our own research in this area.

Original languageEnglish (US)
Pages (from-to)218-227
Number of pages10
JournalOncology
Volume55
Issue number3
DOIs
StatePublished - 1998
Externally publishedYes

Fingerprint

Breast Neoplasms
Drug Therapy
Therapeutics
Inflammatory Breast Neoplasms
Neoplasms
Hematopoietic Stem Cells
Intercellular Signaling Peptides and Proteins
Radiotherapy
Survival Rate
Research

Keywords

  • Locally advanced breast cancer
  • Neoadjuvant chemotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Honkoop, A. H., Wagstaff, J., & Pinedo, H. M. (1998). Management of stage III breast cancer. Oncology, 55(3), 218-227. https://doi.org/10.1159/000011861

Management of stage III breast cancer. / Honkoop, Aafke H.; Wagstaff, John; Pinedo, Herbert M.

In: Oncology, Vol. 55, No. 3, 1998, p. 218-227.

Research output: Contribution to journalArticle

Honkoop, AH, Wagstaff, J & Pinedo, HM 1998, 'Management of stage III breast cancer', Oncology, vol. 55, no. 3, pp. 218-227. https://doi.org/10.1159/000011861
Honkoop AH, Wagstaff J, Pinedo HM. Management of stage III breast cancer. Oncology. 1998;55(3):218-227. https://doi.org/10.1159/000011861
Honkoop, Aafke H. ; Wagstaff, John ; Pinedo, Herbert M. / Management of stage III breast cancer. In: Oncology. 1998 ; Vol. 55, No. 3. pp. 218-227.
@article{48c2e549204843e08208ea427ee3ee5b,
title = "Management of stage III breast cancer",
abstract = "Stage III breast cancer encompasses a heterogenous group of patients. According to the American Joint Committee on Cancer (AJCC) these tumors include stage IIIA and stage IIIB disease, the first generally being operable but the second inoperable. Patients with inflammatory breast cancer are also included in stage IIIB disease, and these patients have the worst prognosis. Multidisciplinary therapy has become the treatment of choice for these patients. Primary or neoadjuvant chemotherapy, followed by locoregional therapy, either surgery, radiotherapy or both, is now an accepted strategy. Most patients achieve a response to chemotherapy, resulting in downstaging of the tumor, and 5-year-survival rates have improved from 10-20{\%} with local therapy alone to 30-60{\%} with the multidisciplinary approach. Although many prospective, mainly phase II trials have been performed in stage III breast cancer, the optimal treatment scheme still has to be established. The role of new therapeutic strategies such as high-dose chemotherapy with hematopoietic stem cell rescue and higher dose intensity regimens with hematopoietic growth factors is currently under investigation. This article will review the literature and discuss our own research in this area.",
keywords = "Locally advanced breast cancer, Neoadjuvant chemotherapy",
author = "Honkoop, {Aafke H.} and John Wagstaff and Pinedo, {Herbert M.}",
year = "1998",
doi = "10.1159/000011861",
language = "English (US)",
volume = "55",
pages = "218--227",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "3",

}

TY - JOUR

T1 - Management of stage III breast cancer

AU - Honkoop, Aafke H.

AU - Wagstaff, John

AU - Pinedo, Herbert M.

PY - 1998

Y1 - 1998

N2 - Stage III breast cancer encompasses a heterogenous group of patients. According to the American Joint Committee on Cancer (AJCC) these tumors include stage IIIA and stage IIIB disease, the first generally being operable but the second inoperable. Patients with inflammatory breast cancer are also included in stage IIIB disease, and these patients have the worst prognosis. Multidisciplinary therapy has become the treatment of choice for these patients. Primary or neoadjuvant chemotherapy, followed by locoregional therapy, either surgery, radiotherapy or both, is now an accepted strategy. Most patients achieve a response to chemotherapy, resulting in downstaging of the tumor, and 5-year-survival rates have improved from 10-20% with local therapy alone to 30-60% with the multidisciplinary approach. Although many prospective, mainly phase II trials have been performed in stage III breast cancer, the optimal treatment scheme still has to be established. The role of new therapeutic strategies such as high-dose chemotherapy with hematopoietic stem cell rescue and higher dose intensity regimens with hematopoietic growth factors is currently under investigation. This article will review the literature and discuss our own research in this area.

AB - Stage III breast cancer encompasses a heterogenous group of patients. According to the American Joint Committee on Cancer (AJCC) these tumors include stage IIIA and stage IIIB disease, the first generally being operable but the second inoperable. Patients with inflammatory breast cancer are also included in stage IIIB disease, and these patients have the worst prognosis. Multidisciplinary therapy has become the treatment of choice for these patients. Primary or neoadjuvant chemotherapy, followed by locoregional therapy, either surgery, radiotherapy or both, is now an accepted strategy. Most patients achieve a response to chemotherapy, resulting in downstaging of the tumor, and 5-year-survival rates have improved from 10-20% with local therapy alone to 30-60% with the multidisciplinary approach. Although many prospective, mainly phase II trials have been performed in stage III breast cancer, the optimal treatment scheme still has to be established. The role of new therapeutic strategies such as high-dose chemotherapy with hematopoietic stem cell rescue and higher dose intensity regimens with hematopoietic growth factors is currently under investigation. This article will review the literature and discuss our own research in this area.

KW - Locally advanced breast cancer

KW - Neoadjuvant chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0031968651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031968651&partnerID=8YFLogxK

U2 - 10.1159/000011861

DO - 10.1159/000011861

M3 - Article

C2 - 9560054

AN - SCOPUS:0031968651

VL - 55

SP - 218

EP - 227

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 3

ER -